Selecxine
Selecxine is a clinical-stage Korean biotech developing immuno-oncology and immunomodulatory antibody therapeutics, led by SLC-3010, a non-covalent IL-2/anti-IL-2 complex currently in Phase I/II trials for solid tumors. The company also operates proprietary Selectope™ and Selectome antibody discovery platforms and an earlier-stage autoimmune pipeline.
- Company typePrivate
- Founded2018
- HeadquartersSongpadong, South Korea
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Selecxine does
Selecxine is a clinical-stage Korean biopharmaceutical company founded in December 2018 by Dr. Jun-Young Lee in Pohang, South Korea, focused on developing immuno-oncology and immunomodulatory therapeutics based on its proprietary antibody-cytokine platform. The company's lead asset, SLC-3010, is a non-covalent complex of human IL-2 and the proprietary TCB2 anti-IL-2 antibody, designed to preferentially activate CD8 T cells and NK cells over regulatory T cells through a triple-action mechanism: direct CD122-biased CD8 activation, suppression of Tregs via free TCB2 intercepting endogenous IL-2, and a tertiary immune re-boosting phase via TCB2 re-conjugation. SLC-3010 received FDA IND clearance in July 2022 and MFDS IND clearance in August 2022, and is currently advancing in Phase I/II investigator-initiated studies across renal cell carcinoma, biliary tract cancer, and gastric cancer. The pipeline is supported by Selectope™, an integrated antibody discovery platform combining phage library generation, cell-based panning, epitope mapping, and characterization, and Selectome, a cell-based functional screening platform featuring the SLC-M13 tool.
Selecxine operates a pre-revenue business model with no disclosed product sales or licensing revenue; the company is funded entirely through equity capital, having raised approximately $55 million across a $12 million Series A (May 2020) and a $30 million Series B (March 2022) led by Stonebridge Ventures with participation from a syndicate of Korean VCs and securities firms. Manufacturing and CMC development are outsourced to GenScript ProBio under a strategic CDMO partnership established in December 2019, and the company is pursuing co-development and licensing partnerships with pharmaceutical companies as its primary path to future revenue, alongside continued engagement with global investors at events such as JPM Healthcare Conference 2026 and Swiss Biotech Day 2026. The company also operates a Seoul research center, opened in August 2019, and an earlier-stage autoimmune pipeline including SLC-7010 (anti-DR3 for Treg expansion) and SLC-7020 (anti-IL-18Rβ for selective IL-18 pathway blockade).
Selecxine firmographics
Firmographics- Name
- Selecxine
- Legal name
- Selecxine Inc.
- Website
- https://selecxine.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Selecxine is a clinical-stage Korean biotech developing immuno-oncology and immunomodulatory antibody therapeutics, led by SLC-3010, a non-covalent IL-2/anti-IL-2 complex currently in Phase I/II trials for solid tumors. The company also operates proprietary Selectope™ and Selectome antibody discovery platforms and an earlier-stage autoimmune pipeline.
- Ownership category
- akta.pro rank
Selecxine industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Bispecific & Multispecific Antibodies (HLAAAAAF)
- akta.pro secondary industry
- Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC)
Keywords
Where Selecxine is headquartered
LocationHeadquarters
- HQ city
- Songpadong
- HQ country
- South Korea
- HQ region
- Asia
Offices2 records
Markets served
Selecxine business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Drug Development & Licensing: As a pre-revenue clinical-stage biotech company, Selecxine is developing proprietary antibody-drug candidates (SLC-3010, SLC-7010, SLC-7020) through clinical development. Revenue generation is anticipated through licensing deals, co-development partnerships, or eventual product sales upon regulatory approval.
- Strategic Partnerships & Collaborations: Revenue may be generated through research collaborations, co-development agreements, and strategic partnerships with pharmaceutical companies for pipeline advancement and commercialization rights.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Selecxine product offering
Product offeringCore offering
Selecxine is a clinical-stage biopharmaceutical company developing proprietary antibody-cytokine therapeutics for immuno-oncology and autoimmune diseases. Its lead candidate SLC-3010 is a non-covalent IL-2/TCB2 antibody complex in Phase I/II clinical trials for solid tumors, supported by earlier-stage pipeline candidates SLC-7010 (anti-DR3) and SLC-7020 (anti-IL-18Rβ) for autoimmune indications, with discovery enabled by its proprietary Selectope™ and Selectome antibody platforms.
Product overview
Selecxine is a biopharmaceutical company developing therapeutic antibodies for cancer treatment based on its proprietary antibody development platforms. The company's core technology includes the Selectope™ integrated functional antibody discovery platform and the Selectome cell-based screening platform. The product portfolio centers on SLC-3010, a non-covalent IL-2/TCB2 antibody complex for immuno-oncology currently in Phase II clinical trials, supported by earlier-stage pipeline candidates SLC-7010 (anti-DR3 for autoimmune diseases) and SLC-7020 (anti-IL-18Rβ for autoimmune diseases). The company also offers the TCB2 antibody as a research tool for immune modulation studies.
Differentiator
Problem solved
Functional benefit
Brands
- Selectope™: Integrated functional antibody discovery platform that combines phage library generation, cell-based panning, epitope mapping, and antibody characterization.
- Selectome
Products and services
- SLC-3010 A non-covalent IL-2/anti-IL-2 (TCB2) antibody complex immuno-oncology candidate designed for preferential activation of CD8 T cells and NK cells over Tregs through its triple-action mechanism; in Phase II clinical development for solid tumor indications including renal cell carcinoma, biliary tract cancer, and gastric cancer.
- SLC-7010 An agonistic anti-DR3 (TNFRSF25) antibody designed for selective expansion of regulatory T cells (Tregs) for autoimmune disease applications.
- SLC-7020 An anti-IL-18Rβ antibody designed to selectively block canonical IL-18 pro-inflammatory signaling while preserving IL-37-mediated anti-inflammatory and immune suppressive activity for autoimmune diseases.
- Selectome Platform A cell-based screening platform enabling highly specific functional antibody selection through physiologically relevant screening methods.
- SLC-M13 A strong research antibody tool enabling highly specific functional antibody selection through physiologically relevant cell-based screening.
- Selectope™ Platform An integrated functional antibody discovery platform that combines phage library generation, cell-based panning, epitope mapping, and antibody characterization for high-value therapeutic antibody development.
- TCB2 (Anti-human IL-2 antibody) A humanized anti-human IL-2 antibody that recognizes the CD25-binding epitope on IL-2, facilitating heterodimeric IL-2 receptor signaling and improving anti-tumor immunity when complexed with IL-2.
Quantifiable outcome
- Up to 5-fold increase in CD8 T cells in NHP PBMC population with non-toxic dose
- +4 more outcomes
Companies that use Selecxine
Customer profileSegments2 records
Ideal customer profiles1 record
Selecxine technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Selecxine partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Daewoong PharmaceuticalcoreSelected as beneficiary company for 2026 Regional Bioindustry Open Innovation Program jointly supported by Pohang City and Daewoong Pharmaceutical. Program provides collaborative research, technology validation, prototype development, testing and analysis, and professional consulting support.
- KoreaBIOminorParticipation in Global IR @ JPM 2026 hosted by KoreaBIO during JP Morgan Healthcare Conference in San Francisco, facilitating cross-border investment and collaboration opportunities with global investors.
- HLB GroupminorOpen innovation collaboration through HLB Group's 1st Pitch Day where Selecxine presented outcomes of collaborative projects and highlighted proprietary Selectope platform and innovative antibody pipelines.
- GenScript ProBiocoreStrategic CDMO partnership for SLC-3010 CMC development, IND-enabling activities, and GMP manufacturing. GenScript ProBio developed customized upstream, downstream, and conjugation processes optimizing manufacturing productivity, purity, and biological activity. Established multiple analytical assays for quality control and product release. Partnership established in December 2019 and expanded for wider range of development processes from stable cell line development to GMP production.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Selecxine competitors and assessment
Company assessmentDirect peers
- Nektar Therapeutics: Nektar Therapeutics developed PEGylated IL-2 (bempegaldesleukin) for cancer immunotherapy, the most prominent prior clinical-stage IL-2 modulator program. Directly comparable to Selecxine's SLC-3010 as a cytokine engineering approach to selectively activate effector T cells.
- Werewolf Therapeutics: Werewolf develops conditionally activated IL-2 and IL-12 prodrugs (WTX-124, WTX-330) for immuno-oncology using a masked cytokine platform. Comparable approach to selective immune activation with reduced peripheral toxicity; a direct peer in engineered cytokine therapeutics.
- Medicenna Therapeutics: Medicenna develops engineered IL-2 and IL-4 Superkines (MDNA11, MDNA55) with biased receptor binding for cancer and autoimmune diseases. Uses similar cytokine modification strategies to Selecxine and competes in the selective IL-2 receptor signaling space.
Emerging players
- Alopexx Oncology: Alopexx Oncology is developing IL-2 and antibody-based immunotherapies in oncology, with a similar CD8-biased mechanism. Compares to Selecxine in attempting to overcome the IL-2 Treg activation limitation through antibody-mediated targeting.
- Cullinan Oncology: Cullinan Oncology is a clinical-stage biotech developing precision oncology medicines including T-cell engagers and immune modulators. Comparable as a focused oncology biotech pursuing differentiated immuno-oncology mechanisms in solid tumors.
- Philogen: Philogen develops antibody-based therapeutics focused on immune-cytokine targeting and targeted cytokines for cancer and inflammatory diseases. Comparable in pursuing selective immune modulation via engineered antibody-cytokine approaches.
Regional players
- ABL Bio: ABL Bio is a Korean clinical-stage biotech developing bispecific antibodies and antibody-drug conjugates for oncology and neurodegenerative diseases. Comparable as a Korean peer with antibody-based therapeutic focus and similar partnership-driven business model.
- ImmuneOncia Therapeutics: ImmuneOncia is a Korean clinical-stage antibody biotech developing immuno-oncology therapeutics including PD-1/PD-L1 antibodies. Closest Korean peer based on geography, business model, and oncology antibody focus.
Broad incumbents
- MacroGenics: MacroGenics develops bispecific antibodies and antibody-based immuno-oncology therapeutics (Margetuximab, Tebotelimab). Comparable as a clinical-stage biotech with proprietary antibody platforms and multiple oncology candidates, though broader in scope than Selecxine.
Others
- GenScript ProBio: GenScript ProBio is Selecxine's CDMO partner providing CMC development and GMP manufacturing for SLC-3010. Comparable as a related ecosystem participant in the biologics manufacturing value chain rather than a direct competitor.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Selecxine social profiles
Digital presenceSelecxine financial estimates
Financial estimateRevenue estimate
Valuation estimate
Selecxine leadership team
Management profileNumber of profiles
Profiles7 records
Selecxine funding detail
Funding detailFunding overview
Funding rounds2 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Selecxine M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Selecxine
What does Selecxine do?
Selecxine is a clinical-stage biopharmaceutical company developing proprietary antibody-cytokine therapeutics for immuno-oncology and autoimmune diseases. Its lead candidate SLC-3010 is a non-covalent IL-2/TCB2 antibody complex in Phase I/II clinical trials for solid tumors, supported by earlier-stage pipeline candidates SLC-7010 (anti-DR3) and SLC-7020 (anti-IL-18Rβ) for autoimmune indications, with discovery enabled by its proprietary Selectope™ and Selectome antibody platforms.
Is Selecxine a public or private company?
Selecxine is a private company. It is classified as venture growth investor backed and is currently operating.
When was Selecxine founded?
Selecxine was founded in 2018. It employs 1 to 10 people.
Where is Selecxine based?
Selecxine is headquartered in Songpadong, South Korea, in the Asia region.
How does Selecxine make money?
Two revenue lines are on record. Drug Development & Licensing is the primary driver. The others are strategic Partnerships & Collaborations.
Who are Selecxine's main competitors?
Direct peers on record are Nektar Therapeutics, Werewolf Therapeutics and Medicenna Therapeutics. Emerging players are Alopexx Oncology, Cullinan Oncology and Philogen. Regional players are ABL Bio and ImmuneOncia Therapeutics. MacroGenics is listed as a broad incumbent. GenScript ProBio is listed as an others.
Does Selecxine have an API?
No public API is recorded for Selecxine.
What industry is Selecxine in?
Selecxine's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAAAAAC, Cytokines, Interferons & Immunomodulatory Proteins. Its NAICS code is 325414 and its SIC code is 2836.